EN
HI
Dr Reddy's Laboratories. Share price
DRREDDY
1174.7
5.30 (-0.45%)NSE
BSE
Last updated on 21 Aug, 2026 | 15:58 IST
Free Demat with Zero AMC*
Open a Free Demat Account
+ Free 1st Year AMC
+ Free 1st Year AMC
Dr Reddy's Laboratories share price chart
Dr Reddy's Laboratories. Share Key Metrics
Volume
12.47 L
Market Cap
98048.58 CR
LTQ@LTP
1@1174.70
ATP
1179.23
Var Margin
12.69 %
Circuit Range
1057.3-1292.1
Delivery %
59.28 %
Value
147.02 CR
ASM/GSM
No
Market Lot
1
Summary
DRREDDY stock price is ₹1174.7 as of 22 Aug, 2026. The stock intraday movement has stayed between ₹1174.00 and ₹1185.10, while Dr Reddy's Laboratories. share price 52 week high low is ₹1101.00 & ₹1414.90.
In terms of trading activity, DRREDDY share price has recorded a volume of 12,46,756 shares. The Dr Reddy's Laboratories. has a market cap of ₹834669070. The stock’s Average Traded Price (ATP) stands at ₹1179.23, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 1 @ ₹1174.70.
The Dr Reddy's Laboratories. upper circuit limit is ₹1292.10 & The Dr Reddy's Laboratories. lower circuit limit is ₹1057.30, with a Value of ₹147.02 CR. The Delivery Percentage for the day is 59.28%.
Additionally, the share currently falls under the No framework, and trades with a market lot size of ₹1.
Dr Reddy's Laboratories. Resistance and Support
Pivot 1178.33
Resistance
First Resistance
1185.46
Second Resistance
1190.93
Third Resistance
1198.06
Support
First Support
1172.86
Second Support
1165.73
Third Support
1160.26
Dr Reddy's Laboratories. Futures & Options
1174.7
-5.3 (-0.45%)
Dr Reddy's Laboratories. Option Chain
View Price, OI, Greeks & More...
25AUG26
1174.60
-3.00 (0.25%)
29SEP26
1175.10
-0.50 (0.04%)
27OCT26
1177.30
-0.50 (0.04%)
DRREDDY|25AUG26 CE 1170.00
7.70
-4.5 (-36.89%)
DRREDDY|25AUG26 PE 1180.00
10.1
-0.1 (-0.98%)
Dr Reddy's Laboratories. Shareholding Pattern
View More- 2016-17
- 2017-18
- 2018-19
- 2019-20
- 2020-21
- 2021-22
- 2022-23
- 2023-24
- 2024-25
- 2025-26
- 2026-27
Total Promoters
Segment
Percent
Total Promoters
26.64%
Mutual Fund
11.14%
Insurance
8.96%
Foreign Institutional Investors
26.85%
Domestic Institutional Investors
2.79%
Retail
10.38%
Others
13.24%
Total Promoters
MAR '24
26.65%
JUN '24
26.65%
SEP '24
26.64%
DEC '24
26.64%
Dr Reddy's Laboratories. Corporate Actions
| Date | Agenda |
|---|---|
| 2026-07-22 | Quarterly Results |
| 2026-05-12 | Audited Results |
| 2026-01-21 | Quarterly Results |
| 2025-10-24 | Quarterly Results |
| 2025-07-23 | Quarterly Results |
| 2025-05-09 | Audited Results |
| 2025-01-23 | Quarterly Results |
| 2024-11-05 | Quarterly Results |
| 2024-07-27 | Quarterly Results & Stock Split |
| Ex Date | Record Date | |
|---|---|---|
| 2026-07-10 | 2026-07-10 | View More |
| Split Ratio | Split Date | |
|---|---|---|
| 5:1 | 2024-10-28 | View More |
Dr Reddy's Laboratories. News
Dr Reddys Laboratories Ltd - 500124 - Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
Dr. Reddy's Laboratories received a USFDA Form 483 with four observations after an inspection at its Bachupally, Hyderabad formulations manufacturing facility. The company will address these observations within the stipulated timeline.
Aug 14 2026 23:29:33
Dr Reddys Laboratories Ltd - 500124 - Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
Dr. Reddys Laboratories announced that the USFDA inspection of its Mirfield API manufacturing facility in the UK has been officially closed. The inspection outcome was classified as 'Voluntary Action Indicated' (VAI), resolving the previous GMP inspection.
Aug 14 2026 23:04:32
Dr Reddys Laboratories Ltd - 500124 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
ICICI Prudential Mutual Fund increased its stake in Dr Reddys Laboratories Ltd. to 5.037% after acquiring 712,884 shares via open market on August 12, 2026. This acquisition led to crossing the 5% ownership threshold.
Aug 14 2026 12:12:22
Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Dr. Reddy's Laboratories announced that the U.S. FDA has approved its rituximab biosimilar. This approval strengthens the company's global biosimilars portfolio and opens up the U.S. market for the product, which will be commercialized by Fresenius Kabi.
Aug 01 2026 09:43:09
Dr Reddys Laboratories Ltd - 500124 - Announcement Under Regulation 30 Of SEBI (LODR) Regulation, 2015
Dr Reddys Laboratories completed a USFDA Pre-Approval Inspection (PAI) and Good Manufacturing Practices (GMP) inspection at its FTO-SEZ Process Unit-02 in Srikakulam, Andhra Pradesh. The company received a Form 483 with three observations, which will be addressed within the stipulated timeline.
Jul 29 2026 21:38:59
Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Dr. Reddy's Laboratories held its Q1 FY27 earnings call, discussing a 5.6% YoY revenue decline and an EBITDA margin of 12.5%. Management expects semaglutide supplies to resume by November, contributing to a strong second half of the fiscal year.
Jul 28 2026 23:08:46
Read More
Dr Reddy's Laboratories. Management
| Name | Position |
|---|---|
| K Randhir Singh | Company Secretary, Compliance Officer and Head-CSR |
| K Satish Reddy | Chairman |
Dr Reddy's Laboratories. Similar Stocks
Lenskart Solutions Ltd.
661.40
6.60 (1.01%)
Zydus Lifesciences Ltd.
1120.00
12.30 (1.11%)
Lupin Ltd.
2201.80
0.30 (0.01%)
Mankind Pharma Ltd.
2384.00
-1.00 (0.04%)
Manipal Health Enterprises Ltd.
715.30
-9.05 (1.25%)
Laurus Labs Ltd.
1802.00
-23.00 (1.26%)
Max Healthcare Institute Ltd.
1000.00
2.10 (0.21%)
Aurobindo Pharma Ltd.
1621.30
13.30 (0.83%)
Aster DM Quality Care Ltd.
761.55
-4.10 (0.54%)
Fortis Healthcare Ltd.
907.10
-9.70 (1.06%)
Dr Reddy's Laboratories. FAQs
The Buying Price of Dr Reddy's Laboratories. share is 1174.7 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.
To buy Dr Reddy's Laboratories. stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Dr Reddy's Laboratories., choose your preferred order type, and place the trade.
The Price-to-earnings (P/E) ratio of Dr Reddy's Laboratories. shares is 30.44. You can compare it with the sector average for relative valuation.
The Price to Book (P/B) ratio Dr Reddy's Laboratories. shares is 2.57. Useful to assess the stock's value relative to its book value.
To assess Dr Reddy's Laboratories.’s valuation compare Sector P/E, P/B which are 68.51 & 3.35 with sector averages, along with growth rates and financial metrics.
The Market Cap of Dr Reddy's Laboratories. is 98048.58 CR. It indicates the company's size category and trading liquidity.
The 52 week high and low prices of Dr Reddy's Laboratories. share price is 1414.90 & 1101.00. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.
Dr Reddy's Laboratories. belongs to the Healthcare sector.
Open Your Free
Demat Account Now!
AMC for First Year
Auto Square Off Charges
Open a Free Demat Account
+ Free 1st Year AMC
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools

Open Your Free
Demat Account Now!
AMC For First Year
Account Opening Fee
Open a Free Demat Account
+ Free 1st Year AMC
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools
Invest in DRREDDY
Account Opening Fee
AMC for 1st Year
Auto Square Off Charges
Call & Trade
Open a Free Demat Account
+ Free 1st Year AMC
+ Free 1st Year AMC